Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Experimental KRAS inhibitor adagrasib also shows activity against lung cancer that has spread to the brain.
Two-year follow-up showed that Lumakras prolonged treatment response and had a favorable safety profile.
A look back at some of the most important science and treatment news Cancer Health covered this year.
Lumakras (sotorasib) was granted accelerated approval for the treatment of advanced non-small-cell lung cancer.
Lumakras led to tumor shrinkage in 36% of NSCLC patients with KRAS G12C mutations.
More than 80% of lung cancer patients treated with the targeted therapy experienced remission or had stable disease.
Sotorasib and adagrasib target a specific cancer-causing mutation found in those with non-small-cell lung cancer and colorectal cancer.
The drug also showed promise for colorectal and other cancers, but it might work better in combination regimens.
To take advantage of these new therapies, people must first learn whether their cancer harbors targetable mutations.
A novel drug that blocks multiple cancer-causing mutations shows promise, especially for combination therapy.
MRTX849 shrank tumors in half of lung cancer patients with a common but difficult to target mutation.
First KRAS targeted therapy shows promise for lung and colon cancer
Half of study participants treated with AMG 510 saw their tumors shrink, and only one experienced disease progression.
AMG 510 shrank tumors in half of lung cancer patients with a mutation thought to be “undruggable.”
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.